Cabaletta Bio Inc
1.55 (14.83%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 1,167,278
Bid Price 11.91
Ask Price 12.22
News -
Day High 12.20


52 Week Range


Day Low 10.79
Company Name Stock Ticker Symbol Market Type
Cabaletta Bio Inc CABA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.55 14.83% 12.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
11.32 10.79 12.20 11.86 10.45
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,537 1,167,278 $ 11.38 $ 13,278,950 - 0.59 - 12.20
Last Trade Time Type Quantity Stock Price Currency
19:59:27 64 $ 12.00 USD


Draw Mode:

Cabaletta Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 349.69M 29.14M 27.68M $ - $ - -1.80 -6.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 366.00k 4.10%

more financials information »

Cabaletta Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CABA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.9012.209.5011.01772,8471.1010.09%
1 Month9.0912.208.2610.30767,1042.9132.01%
3 Months2.4012.201.906.71893,9829.60400.0%
6 Months1.3612.200.592.931,442,71910.64782.35%
1 Year2.8912.200.592.81811,4519.11315.22%
3 Years17.4719.630.594.53386,027-5.47-31.31%
5 Years9.4519.630.594.73365,5762.5526.98%

Cabaletta Bio Description

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.